Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.68 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.54 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.54 |
| ▸ | CRHBP | P24387 | 1/20 | 0.53 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.53 |
| ▸ | CDC25C | P30307 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3146890 | 0.90 | KCNH2 (0.62) | KCNH2PYCR1SIGMAR1TMEM97CRHBP | |
| SCHEMBL17795657 | 0.87 | KCNH2 (0.68) | KCNH2PYCR1SIGMAR1TMEM97CRHBP | |
| SCHEMBL3153147 | 0.84 | KCNH2 (0.68) | KCNH2PYCR1SIGMAR1TMEM97CRHBP | |
| SCHEMBL3156616 | 0.83 | KCNH2 (0.62) | KCNH2PYCR1SIGMAR1TMEM97CRHBP | |
| SCHEMBL3143117 | 0.83 | KCNH2 (0.64) | KCNH2PYCR1SIGMAR1TMEM97CRHBP | |
| SCHEMBL5208558 | 0.83 | KCNH2 (0.71) | KCNH2PYCR1SIGMAR1TMEM97CRHBP | |
| Hydrochloric Acid SCHEMBL11139253 | 0.83 | KCNH2 (0.67) | KCNH2PYCR1SIGMAR1TMEM97CRHBP | |
| SCHEMBL16479584 | 0.82 | KCNH2 (0.61) | KCNH2PYCR1SIGMAR1TMEM97CRHBP | |
| SCHEMBL3156368 | 0.82 | KCNH2 (0.61) | KCNH2PYCR1SIGMAR1TMEM97CRHBP | |
| SCHEMBL11780168 | 0.82 | KCNH2 (0.78) | KCNH2PYCR1SIGMAR1TMEM97CRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224170-B9 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2017-11-22 | — | — | EP | disclosed |
| EP-2157081-A1 | Indolinones substituted in six locations, their manufacture and their application as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2010-02-24 | — | — | EP | disclosed |
| EP-1224170-B1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-08-12 | — | — | EP | disclosed |
| US-6762180-B1 | Substituted indolines which inhibit receptor tyrosine kinases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-07-13 | — | — | US | disclosed |
| EP-1224170-A1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | Boehringer Ingelheim Pharma KG (DE) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001027081-A1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-04-19 | — | — | WO | disclosed |